Zobrazeno 1 - 10
of 441
pro vyhledávání: '"Hiddo J.L. Heerspink"'
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Surrogate endpoints, such as those of interest in chronic kidney disease (CKD), are often evaluated using Bayesian meta-regression. Trials used for the analysis can evaluate a variety of interventions for different sub-classificat
Externí odkaz:
https://doaj.org/article/2415e4fba1da44b68fc33af09146b0c3
Autor:
Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-7 (2023)
Abstract Background This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. Methods Patients with type 2 diabetes and albuminuria were randomized to dapaglifloz
Externí odkaz:
https://doaj.org/article/a6f67e2bdabf4bebb05a41d79f5ed66d
Autor:
Xavier G.L.V. Pouwels, Dominique van Mil, Lyanne M. Kieneker, Cornelis Boersma, Ronald W. van Etten, Birgitte Evers-Roeten, Hiddo J.L. Heerspink, Marc H. Hemmelder, Marloes L.P. Langelaan, Marc H.M. Thelen, Ron T. Gansevoort, Hendrik Koffijberg
Publikováno v:
EClinicalMedicine, Vol 68, Iss , Pp 102414- (2024)
Summary: Background: Chronic kidney disease (CKD) is often detected late, leading to substantial health loss and high treatment costs. Screening the general population for albuminuria identifies individuals at high risk of kidney events and cardiovas
Externí odkaz:
https://doaj.org/article/f179f7ed869b4d75914c3e48acace1d1
Autor:
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J.L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, Vlado Perkovic
Publikováno v:
Kidney International Reports, Vol 8, Iss 5, Pp 1043-1056 (2023)
Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults wit
Externí odkaz:
https://doaj.org/article/25a866cd50534c7d82716666703db077
Autor:
Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Publikováno v:
Kidney International Reports, Vol 7, Iss 3, Pp 436-443 (2022)
Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease (CKD). We performed an analysis of the Dapagliflozin and Prevention of Adv
Externí odkaz:
https://doaj.org/article/1ea3200adb9746dca4e6abb643d67f2e
Autor:
Priya Vart, Hiddo J.L. Heerspink
Publikováno v:
The Lancet Regional Health. Europe, Vol 20, Iss , Pp 100447- (2022)
Externí odkaz:
https://doaj.org/article/3b8b5b2d6cd6423cbf542403b36e0ad2
Autor:
Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain, Ricardo Correa-Rotter
Publikováno v:
Data in Brief, Vol 37, Iss , Pp 107237- (2021)
Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuri
Externí odkaz:
https://doaj.org/article/3e19504c357c42f6a45de1161b69b186
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 212-221 (2019)
Diabetic kidney disease (DKD) is a complex and multifactorial disorder associated with deregulations in a large number of different biological pathways on the molecular level. Using the 2 established biomarkers, estimated glomerular filtration rate (
Externí odkaz:
https://doaj.org/article/7b2292e617664aecbe56656f0634b646
Autor:
Claudia Pontillo, Zhen-Yu Zhang, Joost P. Schanstra, Lotte Jacobs, Petra Zürbig, Lutgarde Thijs, Adela Ramírez-Torres, Hiddo J.L. Heerspink, Morten Lindhardt, Ronald Klein, Trevor Orchard, Massimo Porta, Rudolf W. Bilous, Nishi Charturvedi, Peter Rossing, Antonia Vlahou, Eva Schepers, Griet Glorieux, William Mullen, Christian Delles, Peter Verhamme, Raymond Vanholder, Jan A. Staessen, Harald Mischak, Joachim Jankowski
Publikováno v:
Kidney International Reports, Vol 2, Iss 6, Pp 1066-1075 (2017)
CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to
Externí odkaz:
https://doaj.org/article/cdc6ac8a6105413283d2871d6ecdfc88
Autor:
Sara Sokooti, Tamas Szili-Torok, Jose L. Flores-Guerrero, Maryse C. J. Osté, António W. Gomes-Neto, Jenny E. Kootstra-Ros, Hiddo J.L. Heerspink, Margery A. Connelly, Stephan J. L. Bakker, Robin P. F. Dullaart
Publikováno v:
Biomolecules, Vol 10, Iss 3, p 481 (2020)
High concentrations of high-density lipoprotein (HDL) cholesterol are likely associated with a lower risk of posttransplantation diabetes mellitus (PTDM). However, HDL particles vary in size and density with yet unestablished associations with PTDM r
Externí odkaz:
https://doaj.org/article/1754ca23b82b4039930137a79507dcc2